At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 16, 2026 at 08:00 ET
Lifecore Biomedical reported strong financial results for the seven-month transition period ending December 31, 2025, with revenue up 20% YoY to $75.5 million and Adjusted EBITDA more than quintupling to $13.1 million. Margins expanded significantly due to cost discipline and operational improvements, though net loss remains substantial. The company guided for $120–125 million in revenue for 2026, a decline from pro forma 2025 revenue of $141.4 million, citing customer-specific headwinds.
- Revenue for the seven-month transition period (May 26–Dec 31, 2025) was $75.5 million, up 20% YoY from $63.0 million.
- Gross profit margin improved to 31.4% from 25.9% in the prior-year period, driven by operational initiatives.
- Operating expenses fell 31% YoY to $24.4 million, primarily due to lower SG&A.
- Adjusted EBITDA surged to $13.1 million from $2.6 million in the prior-year period.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access